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Mucosa-associated lymphoid tissue (MALT) lymphomas are a distinct clinico-
pathologic entity mainly associated with chromosomal translocations involving 
the MALT1 gene. Therefore, these chromosomal rearrangements have been 
traditionally used to identify tumor MALT lymphoma B-cells, and they have 
always been detected in differentiated tumoral B cells. However, the 
hematopoietic progenitor and stem cells (HS/PCs) seem not to show any of the 
translocations detected in tumor B cells, although these aberrations would be 
difficult to detect if the frequency of these putative stem cells harboring the 
translocation was low. These results would seem to suggest that the MALT 
lymphoma cell-of-origin, in which the oncogene activation takes place (as a 
result of the mentioned chromosomal rearrangement), is not a stem/progenitor 
cell. However, until now, all the experiments targeting the expression of human 
MALT1 oncogene to the mouse B-cell compartment have failed to reproduce 
the human disease in mice.1 Therefore, it is potentially possible that, in human 
patients, the occurrence of MALTassociated oncogenic alterations might 
happen in the (HS/PCs) compartment, and this cell-of-origin adopts/acquires 
afterwards a MALT lymphoma cell fate as a consequence of the MALT1 activity. 
To elucidate if MALT lymphoma is a stem cell-driven tissue, we developed mice 
in which we limited MALT1 expression to the Sca1+ cells (Sca1-MALT1 mice).2 
Sca1-MALT1 mice developed clonal extranodal B-cell lymphomas recapitulating 
not only the main clinical, histopathological and molecular features of human 
MALT lymphomas, but also the progression to the aggressive form of human 
ABC-DLBCL. These data demonstrate that human MALT lymphoma 
pathogenesis can be modeled in mice by targeting MALT1 expression to the 
HS/PCs compartment, suggesting that a similar scenario may occur in human 
MALT lymphomas. In human MALT lymphoma, like in all human cancers due to 
clonal nature of the disease, the genetic oncogenic alteration is present in all 
the cellular types that compose the tumoral tissue, from the cancer cell-of-origin 
to the terminal differentiated tumor B-cells. In our stem cell-driven Sca1-MALT1 
model, the system has been designed to ensure that the expression of the 
MALT1 oncogene is restricted to the stem/progenitor compartment. In these 
conditions, the expression of the oncogene in the HS/ PCs population is 
nevertheless capable of generating a full-blown MALT lymphoma with all its 
differentiated cellular components. Of course, the demonstration that MALT 
lymphoma development can be established in mice by limiting MALT1 
oncogene expression to Sca1+ cells implies that abolishing oncogene function 
in the differentiated MALT lymphoma tumor cells does not interfere with their 
generation. This suggests that MALT1 enforces a regulatory program in stem 
cells that, in some way, is capable of persisting during hematopoiesis and of 
imposing a tumor phenotype characteristic of MALT lymphoma, an observtion 
that seems to apply to other cancer-initiating gene defects.3-9 Therefore, we 
hypothesize that MALT1 mediates tumorigenesis through epigenetic/genetic 
modification of target genes that remain in this modified state in the mature 
tumor, even in the absence of MALT1 expression, in agreement with a 
reprogramming role for MALT1 in regulating MALT lymphoma formation.  
 
 
This MALT1-mediated reprogramming is, however, permissive, in that it allows 
the normal differentiation of all hematopoietic cell types and only reveals its 
malignant nature in the B cell compartment. In the oncogenic reprogramming 
model presented here, the reprogrammed Sca1+ population can nevertheless 
complete a multistage differentiation pathway involving an initial commitment to 
the B cell lineage and a subsequent differentiation to tumor MALT lymphoma 
cells. This model of cancer is very informative with respect to the fact that the 
oncogenic mutations can have different roles in CSC vs. differentiated cancer 
cells and explains why targeted therapies can eliminate the latter without 
affecting the former. Indeed, our Sca1-MALT1 model suggests that the 
molecular mechanisms of action of MALT1 at the stem cell level will probably be 
different from those acting at later stages of tumoral cell differentiation. But 
perhaps the most crucial question is, how does MALT1 instruct stem cells to 
give rise to a malignant MALT lymphoma cell? In order to identify the genes that 
are associated with MALT1-induced reprogramming of stem cells, we 
performed a supervised analysis of the transcriptional profiles of HS/PCs 
purified from Sca1- MALT1 mice and control mice. The data identified a set of 
genes that are reproducibly differentially regulated in MALT1- targeted stem 
cells vs. control stem cells, showing that Sca1-MALT1-derived HSCs presented 
an abnormal expression of lymphoid-related genes, presumably reflecting their 
cell-intrinsic priming into the lymphoid lineage. Overall, these results show that 
enforced MALT1 expression restricted to stem cells is all that is required to 
generate tumoral MALT cells in mice, therefore suggesting for the first time a 
role for stem/progenitor cells in the pathogenesis of MALT lymphomas. To our 
knowledge, these results represent the most convincing evidence to date that 
MALT lymphoma can arise and be driven by a cell fate change within the stem 
cells. The major questions that arise in light of these findings are how MALT1 
oncogene reprogramming impacts on the target cell, and what are the 
qualitative and/or quantitative figures that make stem/progenitor target cells 
more vulnerable to malignancy. However, the technical approach used here to 
demonstrate that the stem cell compartment drives the pathogenesis of MALT 
lymphoma is not sufficiently stringent to conclusively rule out that expression 
from the transgene is limited to stem cells, as it would be difficult to definitely 
exclude that low levels of expression at certain transitional stages in the mature 
compartments were at the root of the malignancy. Mouse models of cancer 
where precise control of the timing of the oncogene exposure is possible10-12 
will be instrumental to address these and other questions to understand the 
complexity of stem-associated cancers. 
